During the past decade, a significant amount of clarity has been
brought to our understanding of the pathogenesis of non-Hodgkins
lymphoma. Many of the insights gleaned from our knowledge of the
molecular mechanisms that underlie lymphomagenesis have translated
into improved classification schemes. The Working Formulation is a
clinically driven scheme that has long since outlived its
usefulness. It has largely been replaced by the Revised European
and American Lymphoma classification, now known as the REAL proposal.
This scheme recognizes real disease entities that have a
clinical, morphologic, immunophenotypic, cytogenetic, and molecular
genetic correlate. Within each lymphoma category, a spectrum of
clinical behavior may be seen, and this diversity is important to our
understanding of non-Hodgkins lymphoma.
Pathologists welcome this classification, as it focuses on the
biology of these disorders rather than lumping diseases together
based on a common clinical outcome. The information imparted by an
accurate diagnosis, together with the relevant clinical data, can now
be used to make definitive treatment decisions.
The newly developed and more sophisticated techniques for analysis of
lymphoma cells have provided us with the tools necessary for precise
classification of non-Hodgkins lymphoma. Nonetheless, routine
histologic studies remain the gold standard for diagnosis. This
review will focus on the approaches used both for diagnosis and
staging and will attempt to provide some guidelines as to how and
when these tests should be employed.
A well-processed hematoxylin and eosin (H&E) stained section of
an excised lymph node is the mainstay of pathologic diagnosis.
Most often, the diagnosis of difficult lesions relies heavily on a
careful assessment of the underlying architecture. Lymphoma diagnoses
are much less about cytologic detail and far more about altered
architecture. For example, follicular small-cleaved cell lymphoma
(FSC) is characterized by an abundance of neoplastic lymphoid
follicles containing monomorphous small-cleaved lymphocytes. The
individual cells themselves, however, are otherwise typical
smallcleaved lymphocytes seen in the benign follicles of reactive
The loss of normal nodal architecture that accompanies an infiltrate
is of paramount importance in making a diagnosis. An incisional lymph
node provides only a glimpse of the architecture, making
interpretation difficult. Our surgical colleagues must be instructed
to biopsy the most clinically significant site, and whenever
possible, to remove an intact lymph node for pathological processing.
The tissue should be delivered fresh to pathology at an appropriate
time of the day in order to maximize the material for lymphoma
Many hematopathologists prefer to triage the material using imprint
preparations, whereby a fresh cut surface of the node is touched onto
glass slides for Romanowsky staining. Experienced pathologists are
able to make a good approximation of the disease process based on the
touch prep morphology, thus resulting in the efficient ordering of
When the size of the tissue is limiting, the first priority must be
to process the material routinely for fixation and H&E sections.
Properly fixed specimens can be used for regular histologic
examination, paraffin section immunoperoxidase staining, and
depending on the fixative, for gene rearrangement studies by
polymerase chain reaction (PCR). Although B5 is the optimal
fixative for routine lymphoid histology and is preferred for
immunoperoxidase studies, it precludes PCR studies in most
laboratories. Formalin fixation is preferred when the biopsy is small
because all of the above studies, including PCR, can be performed.
Diagnosing Disease at Extranodal SitesApproximately 30%
to 35% of cases of non-Hodgkins lymphoma in adults present
primarily at extranodal sites. Much less is known about the molecular
mechanisms involved in these disorders in comparison to node-based
disease. Therefore, it is important to remember to process extranodal
biopsy material for lymphoma protocol studies whenever there is a
suspicion of a hematolymphoid neoplasm.
Molecular genetic and cytogenetic data from gastric and pulmonary
resection specimens have enormous potential to provide insights into
the pathogenesis of mucosal-associated lymphoid tissue (MALT)
lymphomas but, unfortunately, lymphoma protocol is frequently
overlooked in this setting.[7,8] Nonetheless, examination of a
well-processed H&E section from an excisional biopsy by an
experienced hematopathologist will be sufficient to establish a
diagnosis in the majority of cases.
Needle-core biopsies have a role in lymphoma pathology, although it
remains limited. The use of 14 to 22 gauge needles under
ultrasound or radiological guidance to establish a diagnosis of non-Hodgkins
lymphoma is problematic because of technical difficulties with
biopsy crush artifact, inadequate sampling, and the usual vagaries of
lymphoma pathology. Although this technique has advantages over
fine-needle aspiration (FNA), it should be used judiciously as a
diagnostic tool for patients with suspected non-Hodgkins
lymphoma. Needle-core biopsies do allow a minimal assessment of
architecture in addition to immunostaining procedures, but
interpretation can be problematic in cases of T-cell rich B-cell
lymphoma, angioimmunoblastic-type peripheral T-cell lymphoma, or MALT
lymphoma where much of the lymphoid infiltrate is reactive.
A careful review of most excisional lymph node biopsies demonstrates
marked cytologic and architectural variation throughout the section,
underscoring the complexity of non-Hodgkins lymphoma diagnoses
in what would otherwise be considered routine circumstances.
Needle-core biopsies are unable to detect this variability, leading
to the possibility of incorrect diagnoses in many cases. Although
recent studies have recommended increased use of these techniques,
patient selection and failure to provide convincing evidence that the
right treatment decision was made in the majority of
cases hamper their interpretation.[10,11] Also, many of these studies
included patients with an established diagnosis of either
non-Hodgkins lymphoma or Hodgkins diseasean
approach that differs significantly from a diagnostic procedure.
In managing ill patients or those with significant comorbid disease
who are unable to tolerate an invasive surgical procedure,
needle-core biopsies offer a better alternative to FNA for the
diagnosis of intra-abdominal or thoracic disease. Ideally, two or
three cores should be obtained with one core routinely processed for
histology and the remainder used for lineage and clonality studies.
In this setting, cautious interpretation of the biopsy by an
experienced hematopathologist and integration of the results of the
ancillary studies should allow a reasonable treatment decision to be
made in most cases.
1. Anonymous: National Cancer Institute sponsored study of
classifications of non-Hodgkins lymphomas: Summary and
description of a working formulation for clinical usage. The Non-Hodgkins
Lymphoma Pathologic Classification Project. Cancer 49(10):2112-2135, 1982.
2. Harris NL, Jaffe ES, Stein H, et al: A revised European-American
classification of lymphoid neoplasms: A proposal from the
International Lymphoma Study Group. Blood 84(5):1361-1392, 1994.
3. Hiddemann W, Longo DL, Coiffier B, et al: Lymphoma
classificationthe gap between biology and clinical management
is closing. Blood 88(11):4085-4089, 1996.
4. Jaffe ES: Surgical pathology of the lymph nodes and related
organs. 2nd ed, in Livolsi VA (ed): Major Problems in Pathology, vol
16. Philadelphia, W. B. Saunders Company, 1995.
5. Chhanabhai M, Adomat SA, Gascoyne RD, et al: Clinical utility of
heteroduplex analysis of TCR gamma gene rearrangements in the
diagnosis of T-cell lymphoproliferative disorders. Am J Clin Pathol
6. Isaacson PG, Norton AJ: Extranodal Lymphomas, 1st ed. New York,
Churchill Livingstone, 1994.
7. Auer IA, Gascoyne RD, Connors JM, et al: t(11;18)(q21;q21) is the
most common translocation in MALT lymphomas. Ann Oncol 8(10):979-985, 1997.
8. Ott G, Katzenberger T, Greiner A, et al: The t(11;18)(q21;q21)
chromosome translocation is a frequent and specific aberration in
low-grade but not high-grade malignant non-Hodgkins lymphomas
of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 57(18):3944-3948,
9. Pinkus GS: Needle biopsy in malignant lymphoma (editorial
comment). J Clin Oncol 14(9):2415-2416, 1996.
10. Pappa VI, Hussain HK, Reznek RH, et al: Role of image-guided
core-needle biopsy in the management of patients with lymphoma. J
Clin Oncol 14(9):2427-2430, 1996.
11. Ben-Yehuda D, Polliack A, Okon E, et al: Image-guided core-needle
biopsy in malignant lymphoma: Experience with 100 patients that
suggests the technique is reliable. J Clin Oncol 14(9):2431-2434, 1996.
12. Katz RL: Controvesy in fine-needle aspiration of lymph nodes. A
territorial imperative? Am J Clin Pathol 108(4 suppl 1):S3-5, 1997.
13. Glant MD: Cytopathology of lymph nodes in nonspecific reactive
hyperplasia. Prognostication and differential diagnoses. Am J Clin
Pathol 108(4 suppl 1):S31-55, 1997.
14. Pontifex AH, Klimo P: Application of aspiration biopsy cytology
to lymphomas. Cancer 53(3):553-556, 1984.
15. Kornstein MJ, Wakely PE, Jr, Kardo TF, et al: Dendritic reticulum
cells and immunophenotype in aspiration biopsies of lymph nodes.
Value in the subclassification of non-Hodgkins lymphomas. Am J
Clin Pathol 94(2)165-169, 1990.
16. Cafferty LL, Katz RL, Ordonez NG, et al: Fine-needle aspiration
diagnosis of intraabdominal and retroperitoneal lymphomas by a
morphologic and immunocytochemical approach. Cancer 65(1):72-77, 1990.
17. Majlis A, Pugh WC, Rodriguez MA, et al: Mantle cell lymphoma:
Correlation of clinical outcome and biologic features with three
histologic variants. J Clin Oncol 15(4):1664-1671, 1997.
18. Isaacson PG, Spencer J: Malignant lymphoma of mucosa-associated
lymphoid tissue. Histopathology 11(5):445-462, 1987.
19. Wotherspoon AC, Norton AJ, Lees WR, et al: Diagnostic fine-needle
core biopsy of deep lymph nodes for the diagnosis of lymphoma in
patients unfit for surgery. J Pathol 158(2):115-121, 1989.
20. Jennings CE, Koon KA: Recent advances in flow cytometry:
Application to the diagnosis of hematologic malignancy. Blood
21. Gascoyne RD: Pathologic prognostic factors in diffuse aggressive
non-Hodgkins lymphoma. Hematol Oncol Clin North Am
22. Zukerberg LR, Medeiros LJ, Ferry JA, et al: Diffuse low-grade
B-cell lymphomas. Four clinically distinct subtypes defined by a
combination of morphologic and immunophenotypic features. Am J Clin
Pathol 100(4):373-385, 1993.
23. Pezzella F, Mason DY: The bcl-2 gene and 14;18 translocation in
lymphoproliferative disorders. Nouvelle Revue Francaise
dHematologie 32(6):397-399, 1990.
24. Hill ME, MacLennan KA, Cunningham DC, et al: Prognostic
significance of BCL-2 expression and bcl-2 major breakpoint region
rearrangement in diffuse large cell non-Hodgkins lymphoma: A
British National Lymphoma Investigation Study. Blood 88(3):1046-1051, 1996.
25. Gascoyne RD, Adomat SA, Krajewski S, et al: Prognostic
significance of Bcl-2 protein expression and bcl-2 gene rearrangement
in diffuse aggressive non-Hodgkins lymphoma. Blood
26. Shiota M, Nakamura S, Ichinohasama R, et al: Anaplastic large
cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A
distinct clinicopathologic entity. Blood 86(5):1954-1960, 1995.
27. Yang WI, Zukerberg LR, Motokura T, et al: Cyclin D1 (Bcl-1,
PRAD1) protein expression in low-grade B-cell lymphomas and reactive
hyperplasia. Am J Pathol 145(1):86-86, 1994.
28. Warnke RA, Weiss LM, Chan JKC, et al: Tumors of the lymph nodes
and spleen, 3rd ed, in Rosai J (ed): Atlas of Tumor Pathology, vol
14. Washington, DC, Armed Forces Institute of Pathology, 1994.
29. Cossman J, Uppenkamp M, Sundeen J, et al: Molecular genetics and
the diagnosis of lymphoma. Arch Pathol Lab Med 112(2):117-127, 1988.
30. Bakels V, van Oosteen JW, van der Putte SC, et al:
Immunophenotyping and gene rearrangement analysis provide additional
criteria to differentiate between cutaneous T-cell lymphomas and
pseudo-T-cell lymphomas. Am J Pathol 150(6):1941-1949, 1997.
31. Spencer J, Diss TC, Isaacson PG: Primary B cell gastric lymphoma.
A genotypic analysis. Am J Pathol 135(3):557-564, 1989.
32. Gribben JG, Saporito L, Barber M, et al: Bone marrows of
non-Hodgkins lymphoma patients with a bcl-2 translocation can
be purged of polymerase chain reaction-detectable lymphoma cells
using monoclonal antibodies and immunomagnetic bead depletion. Blood
33. Luthra R, Hai S, Pugh WC: Polymerase chain reaction detection of
the t(11;14) in chronic lymphocytic leukemia and other B-cell
malignancies: A molecular and cytogenetic study. Genes Chromosomes
Cancer 20(1):64-72, 1997.
34. McKeithan TW, Takimoto GS, Ohno H, et al: BCL3 rearrangements and
t(14;19) in chronic lymphocytic leukemia and other B-cell
malignancies: A molecular and cytogenetic study. Genes Chromosomes
Cancer 20(1):64-72, 1997.
35. Michaud GY, Gascoyne RD, McNeil BK, et al: Bcl-6 and
lymphoproliferative disorders. Leuk Lymphoma 26(5-6):515-525, 1997.
36. Morris SW, Kirstein MN, Valentine MB, et al: Fusion of a kinase
gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkins
lymphoma. Science 263(5151):1281-1284, 1994.
37. Fukuhara S, Rowley JD, Variakojis D, et al: Chromosome
abnormalities in poorly differentiated lymphocytic lymphoma. Cancer
Res 39(8):3119-3128, 1979.
38. Tsujimoto Y, Finger LR, Yunis J, et al: Cloning of the chromosome
breakpoint of neoplastic B cells with the t(14;18) chromosome
translocation. Science 226(4678):1097-1099, 1984.
39. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the
BCL2 family and cell death. Blood 88(2):386-401, 1996.
40. Iida S, Rao PH, Nallasivam P, et al: The t(9;14)(p13;q32)
chromosomal translocation associated with lymphoplasmacytoid lymphoma
involves the PAX-5 gene. Blood 88(11)4110-4117, 1996.
41. Coad JE, Olson DJ, Christensen DR, et al: Correlation of
PCR-detected clonal gene rearrangements with bone marrow morphology
in patients with B-cell lineage lymphomas. Am J Surg Pathol
42. Naughton MJ, Hess JL, Zutter MM, et al: Bone marrow staging in
patients with non-Hodgkins lymphoma: Is flow cytometry a useful
test? Cancer 82(6):1154-1159, 1998.
43. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A
clinicopathologic study of 80 cases. Blood 89(6):2067-2078, 1997.